HRP20161312T2 - Postupak za pripravu farmaceutske formulacije kontrastnih sredstava - Google Patents
Postupak za pripravu farmaceutske formulacije kontrastnih sredstava Download PDFInfo
- Publication number
- HRP20161312T2 HRP20161312T2 HRP20161312TT HRP20161312T HRP20161312T2 HR P20161312 T2 HRP20161312 T2 HR P20161312T2 HR P20161312T T HRP20161312T T HR P20161312TT HR P20161312 T HRP20161312 T HR P20161312T HR P20161312 T2 HRP20161312 T2 HR P20161312T2
- Authority
- HR
- Croatia
- Prior art keywords
- free
- macrocyclic chelate
- mol
- lanthanide
- pharmaceutical formulation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 12
- 239000002872 contrast media Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000013522 chelant Substances 0.000 claims 20
- 229910052747 lanthanoid Inorganic materials 0.000 claims 14
- 150000002602 lanthanoids Chemical class 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 239000007788 liquid Substances 0.000 claims 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 6
- 229910052791 calcium Inorganic materials 0.000 claims 6
- 239000011575 calcium Substances 0.000 claims 6
- 229910052688 Gadolinium Inorganic materials 0.000 claims 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 2
- 229960003194 meglumine Drugs 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- GSEKYIWUAPZIEF-UHFFFAOYSA-N Ismine Chemical compound CNC1=CC=CC=C1C(C(=C1)CO)=CC2=C1OCO2 GSEKYIWUAPZIEF-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 150000004697 chelate complex Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003186 pharmaceutical solution Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (12)
1. Postupak za pripravu tekuće farmaceutske formulacije koja sadrži kompleks makrocikličkog kelata s lantanidom i mol/mol količinu slobodnog makrocikličkog kelata između 0.002% i 0.4%, te navedeni postupak sadrži sljedeće uzastopne korake:
b) pripravu tekućeg farmaceutskog pripravka koji sadrži kompleks makrocikličkog kelata s lantanidom, te slobodni makrociklički kelat koji nije u obliku pomoćne tvari X[X',L] gdje L je makrociklički kelat i X i X' su metalni ion, naročito odabran neovisno od kalcija, natrija, cinka i magnezija, i/ili slobodnog lantanida,
pomoću miješanja otopine slobodnog DOTA kao slobodnog makrocikličkog kelata i slobodnog gadolinija kao slobodnog lantanida, tako da se dobije kompleksirani lantanid pomoću makrocikličkog kelata,količine slobodnog makrocikličkog kelata i slobodnog lantanida su takve da se sav lantanid kompleksira i da Cch l > Ct ch l, sa Cch l predstavljaju koncentraciju slobodnog makrocikličkog kelata i Ct ch l predstavljaju ciljanu koncentraciju slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji, Ct ch l je odabran u rasponu od između 0.002 % i 0.4 % mol/mol;
c) mjerenje Cch l u farmaceutskoj formulaciji dobivenoj u koraku b), koncentracija slobodnog lantanida Clan l je jednaka 0;
d) podešavanje Cch l i Clan l pomoću uklanjanja slobodnog makrocikličkog kelata i/ili pomoću dodavanja slobodnog lantanida i/ili modifikacijom pH formulacije dobivene u koraku b) tako da se dobije Cch l = Ct ch l i Clan l = 0,
pri čemu Ct ch l je ciljana koncentracija slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji, te je odabrana u rasponu od između 0.002 % i 0.4 % mol/mol,
naznačen time da količina slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji odgovara udjelu slobodnog makrocikličkog kelata u odnosu na količinu kompleksiranog makrocikličkog kelata DOTA-Gd u konačnoj tekućoj farmaceutskoj formulaciji u mol/mol,pri čemu makrociklički kelat je DOTA i lantanid je gadolinij.
2. Postupak prema zahtjevu 1, naznačen time da je količina mol/mol slobodnog makrocikličkog kelata između 0.025% i 0.25%.
3. Postupak prema bilo kojem zahtjevu od 1 i 2, naznačen time da farmaceutska formulacija je farmaceutska formulacija megluminske soli kompleksa DOTA-gadolinij.
4. Postupak prema zahtjeva 3, naznačen time da korak podešavanja d) na kraju sadrži korak podešavanja pH i volumena, s megluminom.
5. Postupak prema bilo kojem zahtjevu od 1 do 4, naznačen time da se korak b) provodi na temperaturi od između 60°C i 100°C, poželjno 80°C.
6. Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time da su u koraku b) dodane količine slobodnog makrocikličkog kelata i slobodnog lantanida takve da je omjer slobodnog makrocikličkog kelata / slobodni lantanid mol/mol između 1.001 i 1.3.
7. Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time da su u koraku b) dodane količine slobodnog makrocikličkog kelata i slobodnog lantanida takve da je omjer slobodnog makrocikličkog kelata / slobodni lantanid (mol/mol) između 1.005 i 1.02.
8. Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time da je količina kalcija u tekućoj farmaceutskoj formulaciji koja se daje pacijentu manja od 50 ppm, poželjno manja od 20 ppm, još poželjnije manja od 5 ppm.
9. Postupak prema zahtjevu 8, naznačen time da je količina kalcija u tekućoj farmaceutskoj formulaciji koja se daje pacijentu manja od 50 ppm i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu u koraku b), odnosno za DOTA prašak, vodi i megluminu, manja od 20 ppm, poželjno manja od 15 ppm.
10. Postupak prema bilo kojem zahtjevu od 8 ili 9, naznačen time da prije koraka c) sadrži, međukorak b2) mjerenja količine kalcija, te gdje je to prikladno, uklanjanje suvišnog kalcija.
11. Postupak prema bilo kojem zahtjevu od 1 do 10, naznačen time da sadrži dodatni korak e) provjere Cch l i Clan l.
12. Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time da se korak b) provodi kod temperature od između 60°C i 100°C i time da se farmaceutska formulacija zatim hladi prije koraka podešavanja d).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0851055A FR2927539B1 (fr) | 2008-02-19 | 2008-02-19 | Procede de preparation d'une formulation pharmaceutique d'agents de contraste. |
| EP08154745 | 2008-04-17 | ||
| US12/155,997 US20090208421A1 (en) | 2008-02-19 | 2008-06-12 | Process for preparing a pharmaceutical formulation of contrast agents |
| EP14165006.9A EP2799089B9 (en) | 2008-02-19 | 2009-02-18 | Process for preparing a pharmaceutical formulation of contrast agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20161312T1 HRP20161312T1 (hr) | 2016-12-16 |
| HRP20161312T2 true HRP20161312T2 (hr) | 2018-01-26 |
Family
ID=40955314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140537AT HRP20140537T1 (hr) | 2008-02-19 | 2014-06-09 | Postupak za pripravu farmaceutske formulacije kontrastnih sredstava |
| HRP20161312TT HRP20161312T2 (hr) | 2008-02-19 | 2016-10-11 | Postupak za pripravu farmaceutske formulacije kontrastnih sredstava |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140537AT HRP20140537T1 (hr) | 2008-02-19 | 2014-06-09 | Postupak za pripravu farmaceutske formulacije kontrastnih sredstava |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20090208421A1 (hr) |
| EP (6) | EP2799090B2 (hr) |
| JP (3) | JP5469615B2 (hr) |
| KR (1) | KR101063060B1 (hr) |
| CN (1) | CN101977633B (hr) |
| BR (1) | BRPI0908221B1 (hr) |
| CA (1) | CA2714118C (hr) |
| CY (2) | CY1115259T1 (hr) |
| DE (1) | DE202008010019U1 (hr) |
| DK (3) | DK2242515T3 (hr) |
| ES (3) | ES2597782T3 (hr) |
| HR (2) | HRP20140537T1 (hr) |
| HU (2) | HUE030219T2 (hr) |
| LT (2) | LT2799090T (hr) |
| PL (3) | PL2242515T3 (hr) |
| PT (3) | PT2799090T (hr) |
| WO (1) | WO2009103744A2 (hr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
| FR2945448B1 (fr) | 2009-05-13 | 2012-08-31 | Guerbet Sa | Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre. |
| EP2338874A1 (en) | 2009-12-16 | 2011-06-29 | Bracco Imaging S.p.A | Process for the preparation of chelated compounds |
| HUE051988T2 (hu) * | 2013-01-07 | 2021-04-28 | Univ Pennsylvania | Készítmények és eljárások bõr T-sejt lymphoma kezelésére |
| TW201514188A (zh) * | 2013-03-13 | 2015-04-16 | Lantheus Medical Imaging Inc | 製備釓磷維塞三鈉單水合物之方法 |
| EP2786768A1 (en) | 2013-04-04 | 2014-10-08 | Agfa Healthcare | Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide |
| HUE033219T2 (en) | 2013-04-26 | 2017-11-28 | Guerbet Sa | Contrast medium preparation and related preparation process |
| KR101466602B1 (ko) * | 2013-05-31 | 2014-12-01 | 동국제약 주식회사 | 메글루민 가도테레이트를 포함하는 조영제 조성물의 제조방법 |
| AT516104B1 (de) * | 2014-07-31 | 2016-08-15 | Sanochemia Pharmazeutika Ag | Verfahren zum Herstellen einer flüssigen pharmazeutischen Zubereitung |
| KR101646211B1 (ko) * | 2014-11-12 | 2016-08-05 | (주)디아이테크 | 자기공명영상용 조영제의 제조방법 |
| GB201421161D0 (en) * | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Metal complex formulations |
| GB201421163D0 (en) * | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Formulations of metal complexes |
| GB201421162D0 (en) * | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Lanthanide complex formulations |
| US20170035461A1 (en) * | 2015-08-03 | 2017-02-09 | Jeffery Deal | Reversible tattoo colorant and method |
| DE102015013939A1 (de) * | 2015-09-15 | 2017-03-16 | be imaging GmbH | Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen |
| WO2017059092A1 (en) | 2015-09-30 | 2017-04-06 | Duke University | Ascorbate formulations and methods of use as contrast agents |
| KR101625656B1 (ko) * | 2015-10-16 | 2016-05-30 | 최경석 | 자기공명영상용 조영제의 제조방법 |
| CN108289970B (zh) * | 2015-11-30 | 2022-04-08 | 通用电气医疗集团股份有限公司 | 包含mri造影剂的组合的制剂 |
| GB201610738D0 (en) | 2016-06-20 | 2016-08-03 | Ge Healthcare As | Chelate compounds |
| WO2018069176A1 (en) | 2016-10-12 | 2018-04-19 | T2Pharma Gmbh | Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates |
| WO2018069179A1 (en) | 2016-10-12 | 2018-04-19 | T2Pharma Gmbh | Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates |
| EP3315141B1 (de) * | 2016-10-28 | 2020-10-21 | B.E. Imaging GmbH | Verfahren zur herstellung von pharmazeutischen formulierungen enthaltend chelatkomplexe von gadolinium mit reduziertem gehalt an toxischen verunreinigungen |
| CN110035996B (zh) | 2016-11-28 | 2022-08-09 | 拜耳医药股份公司 | 用于磁共振成像的新型高弛豫性钆螯合物 |
| ES2813077T3 (es) | 2016-12-21 | 2021-03-22 | Ge Healthcare As | Compuestos quelatos de manganeso basados en macrociclo de tetraazabiciclo adecuados como agentes de imagen de IRM |
| US20180185521A1 (en) * | 2016-12-29 | 2018-07-05 | Inventure, LLC | Solvent-Free Gadolinium Contrast Agents |
| US20190269805A1 (en) * | 2016-12-29 | 2019-09-05 | Inventure, LLC | Solvent-free gadolinium contrast agents |
| US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| JP7191938B2 (ja) | 2017-05-05 | 2022-12-19 | センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション | Ｉｇｆ－１ｒモノクローナル抗体及びその使用 |
| RU2019139432A (ru) | 2017-05-05 | 2021-06-07 | Сентр фор Проуб Девелопмент энд Коммерсиализэйшн | Фармакокинетическая оптимизация бифункциональных хелатов и их применение |
| WO2019020662A1 (de) * | 2017-07-27 | 2019-01-31 | Sanochemia Pharmazeutika Ag | Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen |
| FR3072281B1 (fr) * | 2017-10-13 | 2020-12-04 | Nh Theraguix | Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs |
| EP3728168B1 (en) | 2017-12-20 | 2022-03-30 | General Electric Company | Anionic chelate compounds |
| AT521001B1 (de) * | 2018-02-23 | 2020-10-15 | Sanochemia Pharmazeutika Ag | Herstellungsverfahren für ein Kontrastmittel |
| KR20210095168A (ko) | 2018-11-23 | 2021-07-30 | 바이엘 악티엔게젤샤프트 | 조영 매체의 제형 및 그의 제조 방법 |
| CN113939740A (zh) * | 2019-01-03 | 2022-01-14 | 离子路径公司 | 用于离子束成像的组合物和试剂 |
| FR3091873B1 (fr) * | 2019-01-17 | 2020-12-25 | Guerbet Sa | Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification |
| EP4048322A1 (en) * | 2019-10-25 | 2022-08-31 | Bracco Imaging SPA | Pharmaceutical compositions of gd-based contrast agents |
| GB201919073D0 (en) | 2019-12-20 | 2020-02-05 | Ge Healthcare As | Novel manufacturing process |
| TWI779284B (zh) * | 2020-05-06 | 2022-10-01 | 商之器科技股份有限公司 | 用於影像資料標註的裝置 |
| CA3181564A1 (en) | 2020-06-10 | 2021-12-16 | Ignacio Alonso Silva | Procedure for obtaining gadoterate meglumine from high-purity tetraxetan (dota) and its use in the preparation of injectable galenical formulations |
| CN113801071B (zh) * | 2021-09-14 | 2023-04-07 | 安徽普利药业有限公司 | 一种钆特酸葡甲胺的精制方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) * | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| NL194579C (nl) * | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostisch middel. |
| US4639365A (en) | 1984-10-18 | 1987-01-27 | The Board Of Regents, The University Of Texas System | Gadolinium chelates as NMR contrast agents |
| US5082649A (en) | 1987-06-30 | 1992-01-21 | Mallinckrodt Medical, Inc. | Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions |
| FR2596992B1 (fr) * | 1986-04-11 | 1988-12-16 | Guerbet Sa | Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic |
| DE3640708C2 (de) * | 1986-11-28 | 1995-05-18 | Schering Ag | Verbesserte metallhaltige Pharmazeutika |
| US5049667A (en) | 1987-04-14 | 1991-09-17 | Guerbet S.A. | Nitrogen-containing cyclic ligands |
| WO1989000052A1 (en) * | 1987-06-30 | 1989-01-12 | Mallinckrodt, Inc. | Method for enhancing the safety of metal-ligand chelates as magnetic resonants imaging agents and x-ray contrast agents |
| JP2854905B2 (ja) * | 1988-09-27 | 1999-02-10 | サリユーター・インコーポレイテツド | キレート組成物 |
| JPH02173483A (ja) | 1988-12-23 | 1990-07-04 | Komatsu Ltd | 高速流量制御弁 |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US4967447A (en) | 1989-09-25 | 1990-11-06 | Romaine Jeffrey L | Fish slicer and method of frying fish |
| US5650133A (en) | 1990-01-19 | 1997-07-22 | Nycomed Salutar | Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality |
| GB9000564D0 (en) | 1990-01-10 | 1990-03-14 | Dow Rheinmuenster | Modified polyoxyethlene epoxy resin amphiphiles and stable aqueous epoxy dispersions thereof |
| GB9001245D0 (en) † | 1990-01-19 | 1990-03-21 | Salutar Inc | Compounds |
| US7385041B2 (en) * | 1990-04-25 | 2008-06-10 | Bracco International B.V. | Dual functioning excipient for metal chelate contrast agents |
| CA2039399C (en) | 1990-04-25 | 2000-09-05 | C. Allen Chang | Dual functioning excipient for metal chelate contrast agents |
| CA2117775A1 (en) | 1992-04-13 | 1993-10-28 | Roberta C. Cheng | Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof |
| GB9318550D0 (en) | 1993-09-07 | 1993-10-20 | Nycomed Salutar Inc | Chelants |
| FR2736051B3 (fr) * | 1995-06-29 | 1997-09-26 | Guerbet Sa | Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique |
| US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
| US7048907B2 (en) * | 2001-02-05 | 2006-05-23 | Biophysics Assay Laboratory, Inc. | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products |
| TWI240632B (en) | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
| JP2005534697A (ja) * | 2002-08-06 | 2005-11-17 | エピックス ファーマシューティカルズ， インコーポレイテッド | ペプチド凝集体 |
| WO2007002109A2 (en) | 2005-06-20 | 2007-01-04 | The Regents Of The University Of California | Multidentate pyrone-derived chelators for medicinal imaging and chelation |
| EP1940841B9 (fr) | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
| EP1993613A2 (en) | 2006-03-15 | 2008-11-26 | Mallinckrodt, Inc. | Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
| WO2007121453A2 (en) * | 2006-04-17 | 2007-10-25 | The Regents Of The University Of California | 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents |
| US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
-
2008
- 2008-06-12 US US12/155,997 patent/US20090208421A1/en not_active Abandoned
- 2008-07-25 DE DE202008010019U patent/DE202008010019U1/de not_active Withdrawn - After Issue
-
2009
- 2009-02-18 ES ES14165006.9T patent/ES2597782T3/es active Active
- 2009-02-18 HU HUE14165006A patent/HUE030219T2/en unknown
- 2009-02-18 DK DK09712403.6T patent/DK2242515T3/da active
- 2009-02-18 PT PT141650085T patent/PT2799090T/pt unknown
- 2009-02-18 DK DK14165006.9T patent/DK2799089T3/en active
- 2009-02-18 US US12/918,259 patent/US9655983B2/en active Active
- 2009-02-18 EP EP14165008.5A patent/EP2799090B2/en active Active
- 2009-02-18 EP EP09712403.6A patent/EP2242515B9/en not_active Revoked
- 2009-02-18 PT PT97124036T patent/PT2242515E/pt unknown
- 2009-02-18 CN CN2009801096136A patent/CN101977633B/zh active Active
- 2009-02-18 JP JP2010547173A patent/JP5469615B2/ja active Active
- 2009-02-18 ES ES09712403.6T patent/ES2477541T3/es active Active
- 2009-02-18 LT LTEP14165008.5T patent/LT2799090T/lt unknown
- 2009-02-18 WO PCT/EP2009/051937 patent/WO2009103744A2/en active Application Filing
- 2009-02-18 ES ES14165008T patent/ES2593127T5/es active Active
- 2009-02-18 CA CA2714118A patent/CA2714118C/en active Active
- 2009-02-18 PL PL09712403T patent/PL2242515T3/pl unknown
- 2009-02-18 EP EP16194654.6A patent/EP3159014A1/en not_active Ceased
- 2009-02-18 PL PL14165006T patent/PL2799089T3/pl unknown
- 2009-02-18 PT PT141650069T patent/PT2799089T/pt unknown
- 2009-02-18 BR BRPI0908221-2A patent/BRPI0908221B1/pt active IP Right Grant
- 2009-02-18 EP EP13154448.8A patent/EP2591807A1/en not_active Ceased
- 2009-02-18 KR KR1020107020477A patent/KR101063060B1/ko active IP Right Review Request
- 2009-02-18 EP EP19204417.0A patent/EP3620179A1/en not_active Withdrawn
- 2009-02-18 EP EP14165006.9A patent/EP2799089B9/en not_active Revoked
- 2009-02-18 PL PL14165008.5T patent/PL2799090T5/pl unknown
- 2009-02-18 HU HUE14165008A patent/HUE031091T2/en unknown
- 2009-02-18 LT LTEP14165006.9T patent/LT2799089T/lt unknown
- 2009-02-18 DK DK14165008.5T patent/DK2799090T4/da active
-
2013
- 2013-08-20 US US13/971,672 patent/US20130336898A1/en not_active Abandoned
-
2014
- 2014-01-30 JP JP2014015276A patent/JP5985523B2/ja active Active
- 2014-06-09 HR HRP20140537AT patent/HRP20140537T1/hr unknown
- 2014-07-01 CY CY20141100489T patent/CY1115259T1/el unknown
-
2016
- 2016-03-30 JP JP2016066978A patent/JP6422460B2/ja active Active
- 2016-04-27 US US15/140,077 patent/US9636427B2/en active Active
- 2016-04-27 US US15/140,132 patent/US20160235868A1/en not_active Abandoned
- 2016-10-11 HR HRP20161312TT patent/HRP20161312T2/hr unknown
- 2016-11-03 CY CY20161101126T patent/CY1118985T1/el unknown
-
2017
- 2017-03-22 US US15/466,600 patent/US9907866B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161312T2 (hr) | Postupak za pripravu farmaceutske formulacije kontrastnih sredstava | |
| Shahid et al. | Glass ionomer cements: effect of strontium substitution on esthetics, radiopacity and fluoride release | |
| Loncin et al. | Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes | |
| Bramante et al. | Presence of arsenic in different types of MTA and white and gray Portland cement | |
| Duarte et al. | Arsenic release provided by MTA and Portland cement | |
| Bueno et al. | Positive correlation between fluoride release and acid erosion of restorative glass-ionomer cements | |
| Miller | Treatment of osteoporosis in chronic kidney disease and end-stage renal disease | |
| Toporivska et al. | The solution thermodynamic stability of desferrioxamine B (DFO) with Zr (IV) | |
| WO2014161925A1 (en) | Process for producing a complex of a lanthanide with a macrocyclic ligand | |
| DE102015013939A1 (de) | Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen | |
| Hayacibara et al. | Simultaneous release of fluoride and aluminum from dental materials in various immersion media | |
| US10064961B2 (en) | Method for producing a liquid pharmaceutical preparation | |
| JPS6034903A (ja) | 歯科用セメント組成物 | |
| Dedhiya et al. | Mechanism of hydroxyapatite dissolution. Synergistic effects of solution fluoride, strontium, and phosphate | |
| Gonçalves et al. | Evaluation of physico-chemical properties of Portland cements and MTA | |
| Yantasee et al. | Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis | |
| Nicholson et al. | Maturation affects fluoride uptake by glass-ionomer dental cements | |
| Singbal et al. | Cention N Compared to Other Contemporary Tooth-Colored Restorative Materials in Terms of Fluoride Ion Releasing Efficacy: Validation of a Novel Caries-Prevention-Initiative by the Ministry of Health, Malaysia | |
| Procházková et al. | Formation kinetics of europium (III) complexes of DOTA and its bis (phosphonate) bearing analogs | |
| US9445973B2 (en) | Dental filling composition comprising zirconia powder | |
| EP3153162A1 (en) | Preparation of pharmaceutical dosage forms containing iron (iii) salts | |
| Ševčíková et al. | Kinetic study of formation/dissociation of Cu (II) and Zn (II) complexes of cyclen macrocyclic ligand with pendant thiol group | |
| CN103385882B (zh) | 一种伊班膦酸钠注射用组合物 | |
| US20060234878A1 (en) | Additive for reducing chromium (vi) ions to chromium (iii) ions | |
| Lewis et al. | Interaction of fluoride complexes derived from glass-ionomer cements with hydroxyapatite |